Invesco
ALLO icon

Invesco’s Allogene Therapeutics ALLO Stock Holding History

Invesco’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
772,786
+88,267
+13% +$194K ﹤0.01% 2678
2026
Q1 		$1.67M Buy
684,519
+74,712
+12% +$150K ﹤0.01% 2626
2025
Q4 		$835K Buy
609,807
+84,494
+16% +$111K ﹤0.01% 2989
2025
Q3 		$651K Buy
525,313
+128,801
+32% +$154K ﹤0.01% 3123
2025
Q2 		$448K Buy
396,512
+111,305
+39% +$148K ﹤0.01% 3202
2025
Q1 		$416K Buy
285,207
+157,721
+124% +$297K ﹤0.01% 3225
2024
Q4 		$272K Buy
127,486
+8,359
+7% +$20.6K ﹤0.01% 3445
2024
Q3 		$334K Sell
119,127
-1,011
-0.8% -$2.69K ﹤0.01% 3383
2024
Q2 		$280K Sell
120,138
-545
-0.5% -$1.61K ﹤0.01% 3529
2024
Q1 		$539K Buy
120,683
+18,707
+18% +$78.1K ﹤0.01% 3292
2023
Q4 		$327K Buy
101,976
+8,464
+9% +$24K ﹤0.01% 3404
2023
Q3 		$296K Buy
93,512
+1,242
+1% +$5.44K ﹤0.01% 3464
2023
Q2 		$459K Sell
92,270
-2,738
-3% -$14.8K ﹤0.01% 3286
2023
Q1 		$469K Buy
95,008
+5,201
+6% +$33.4K ﹤0.01% 3294
2022
Q4 		$565K Sell
89,807
-384
-0.4% -$3.56K ﹤0.01% 3206
2022
Q3 		$974K Sell
90,191
-507,974
-85% -$6.9M ﹤0.01% 2935
2022
Q2 		$6.82M Buy
598,165
+515,612
+625% +$4.58M ﹤0.01% 2107
2022
Q1 		$751K Buy
82,553
+45,352
+122% +$472K ﹤0.01% 3208
2021
Q4 		$556K Buy
37,201
+2,091
+6% +$36.9K ﹤0.01% 3345
2021
Q3 		$902K Sell
35,110
-4,301
-11% -$102K ﹤0.01% 3153
2021
Q2 		$1.03M Buy
39,411
+18,236
+86% +$520K ﹤0.01% 3114
2021
Q1 		$747K Buy
21,175
+848
+4% +$28.6K ﹤0.01% 3172
2020
Q4 		$513K Buy
20,327
+7,896
+64% +$257K ﹤0.01% 3191
2020
Q3 		$468K Sell
12,431
-176
-1% -$6.64K ﹤0.01% 3142
2020
Q2 		$539K Sell
12,607
-1,123
-8% -$40.6K ﹤0.01% 3093
2020
Q1 		$267K Buy
+13,730
New +$327K ﹤0.01% 3309

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Invesco's ALLO Position: Q2 2026 in Review

Invesco increased its Allogene Therapeutics (ALLO) stake by 13% in Q2 2026, buying an estimated $194K and bringing the position to 772,786 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2678.

Invesco first reported a position in ALLO in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.82M in Q2 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Invesco held 772,786 shares of Allogene Therapeutics worth $1.61M as of Q2 2026.
  • Invesco bought 88,267 Allogene Therapeutics shares in Q2 2026, an estimated $194K.
  • Allogene Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2678 holding.
  • Invesco first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Invesco's Allogene Therapeutics position peaked at $6.82M in Q2 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.